Subir Prasad, MD
Neurology · Nashville, TNNPI 1417958695
Payments from drug & device makers
Across 299 payments — averaging $83.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- Sanofi US Services Inc.$4K
- Banner Life Sciences, LLC$926
- Biogen$695
- Supernus Pharmaceuticals, Inc.$409
- Lilly USA, LLC$310
- plus $2K from 28 others
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$18,53674%
- Travel & lodging$1,3005%
- Food & beverage$4,74919%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $16,154 |
| Sanofi US Services Inc. | 7 | $4,046 |
| Banner Life Sciences, LLC | 3 | $926 |
| Biogen | 26 | $695 |
| Supernus Pharmaceuticals, Inc. | 31 | $409 |
| Lilly USA, LLC | 21 | $310 |
| AstraZeneca(2 entities) | 17 | $303 |
| Teva Pharmaceuticals USA, Inc. | 30 | $283 |
| EMD Serono, Inc. | 12 | $215 |
| Amgen | 13 | $196 |
| Acadia Pharmaceuticals Inc | 11 | $185 |
| Biohaven Pharmaceuticals, Inc. | 7 | $183 |
| Kyowa Kirin, Inc. | 8 | $138 |
| Novartis | 7 | $109 |
| Neurocrine Biosciences, Inc. | 4 | $78 |
| Sunovion Pharmaceuticals Inc. | 4 | $74 |
| Pfizer | 2 | $72 |
| Johnson & Johnson | 5 | $70 |
| Bristol Myers Squibb | 5 | $69 |
| Lundbeck LLC | 4 | $58 |
| CSL Behring | 2 | $44 |
| Adamas Pharmaceuticals, Inc. | 2 | $41 |
| Upsher-smith Laboratories LLC | 3 | $37 |
| Merz North America, Inc. | 2 | $35 |
| Genentech USA, Inc. | 2 | $34 |
| Vertical Pharmaceuticals, LLC | 2 | $29 |
| MDD US Operations, LLC | 1 | $29 |
| Currax Pharmaceuticals LLC | 2 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Argenx US, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $14 |
| Acorda Therapeutics, Inc | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$14,951
- NO PRODUCT DISCUSSED$3,876
- Bafiertam$900
- TYSABRI$300
- QULIPTA$300
How this compares
$24,940 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 29 | $283,654 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $78,704 |
| UbrelvyUbrogepant | 46 | $45,914 |
| Nurtec OdtRimegepant Sulfate | 14 | $23,457 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $13,949 |
| BotoxOnabotulinumtoxina | 13 | $13,846 |
| Entacapone | 105 | $11,271 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 18 | $10,050 |
| Emgality PenGalcanezumab-Gnlm | 12 | $7,680 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 219 | $6,492 |
| Galantamine Hbr | 208 | $6,421 |
| Levetiracetam | 145 | $6,157 |
| Gabapentin | 208 | $4,607 |
| Sumatriptan Succinate | 45 | $4,493 |
| Ropinirole Hcl | 223 | $4,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $44 | $283,65429 claims |
| AbbVieUbrelvy, Botox | $16,154 | $59,76059 claims |
| PfizerNurtec Odt | $72 | $23,45714 claims |
| Upsher-smith Laboratories LLCTopiramate | $37 | $3,406213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.
Other neurology in Nashville
- Daniel ClaassenNashville$3.5M
- Siddharama PawateNashville$2M
- John FangNashville$1.5M
- Lealani AcostaNashville$1.4M
- Amy BrownNashville$895K
- Katherine McDonellNashville$862K
- Harold MosesNashville$778K
- Philip CharlesNashville$700K
- Shilpi MittalNashville$481K
- Francesca BagnatoNashville$378K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.